Meeting
2012 ASCO Annual Meeting
Determinants of and outcomes associated with chemoimmunotherapy dose density in elderly subjects with diffuse large B-cell lymphoma (DLBCL).
Authors
Usha S. Perepu
University of Iowa Hospitals and Clinics, Iowa City, IA
Usha S. Perepu , Kelcy C Weibel , Anna M Button , Laura S. Jacobus , Brian Smith , James R. Cerhan , Brian K. Link
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Citation
J Clin Oncol 30, 2012 (suppl; abstr 8061)
DOI
10.1200/jco.2012.30.15_suppl.8061
Abstract #
8061
Poster Bd #
34B
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Glofitamab + Pola-R-CHP in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): Results from a phase Ib study.
First Author: Michael Dickinson
Poster
2022 ASCO Annual Meeting
Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma.
First Author: Hua-Jay Jeffery Cherng
Poster
2023 ASCO Annual Meeting
Subgroup analysis of elderly patients (pts) with diffuse large B-cell lymphoma (DLBCL) in the phase 3 POLARIX study.
First Author: Bei Hu
Poster
2023 ASCO Annual Meeting
Phase II trial of split-dose R-CHOP for older patients with diffuse large B-cell lymphoma (DLBCL).
First Author: Nirav Niranjan Shah